drugset
drugset / Trial / NCT02822586

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

NCT02822586 ↗

Phase 1 Completed 5 enrolled Virginia Commonwealth University Seagen Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the cutaneous toxicity and treatment response associated with administering concurrent TSEB and brentuximab vedotin in patients with mycosis fungoides or Sézary Syndrome.

Timeline

Start
2016-12-19
Primary completion
2019-04-29
Completion
2019-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Brentuximab Vedotin Monoclonal antibody 1.8 mg/kg Intravenous

Indications

Sezary syndrome mycosis fungoides